Skip to content
Explicyte Oncology CRO logo
  • Discovery

    FFPE target discovery

    Custom biospecimen sourcing

    Target identification & ranking

    Target expression profiling

    Data generation

    AI-ready Spatial Biology Datasets

    Explicyte 10x Genomics certified service provider

    Across Visium, Xenium, Chromium

    Explore 10x services →

    Emerging IO Targets: pipeline overview

    Browse database →
  • Preclinical

    Functional efficacy and MoA

    Tumor killing assays

    ADCC · T-cell · Antigen-specific

    Immune function & modulation

    Activation · Migration · MLR · Macrophage Polarization · Germinal Center Reaction

    Safety

    Cytokine release

    Additional capabilities

    Patient-Derived 3D tumor models

    Immune-native organoids · Tumor fragments

    Modality-specific assays

    ADCs · Multispecifics & engagers

    Xenium for cells

  • Trials

    Biomarker analysis

    Transcriptomic biomarkers

    Spatial transcriptomics · scRNAseq

    ISO-certified pathology services

    IHC/IF assay development · Assay validation · TLS scoring

    Peripheral biomarkers

    Proteomics · Flow cytometry · scRNAseq

    Explicyte is ISO 9001 and ISO 13485 certified for biomarker and immuno-oncology services

    Certified IHC/IF biomarker services

    Clinical-grade quality management

    Our tissue biomarker services →

    Explicyte 10x Genomics certified service provider

    10x Genomics-Certified Services

    Chromium X, Visium HD, Xenium

    Explore 10x-certified services →

  • Resources

    Publications

    Case studies

    Posters & abstracts

    IO Target Database

    Events & webinars

    News & press

  • About

    Company

    Commitments

    Careers

MultiOmics
Contact us

Resources / MaaT Pharma: Advancing a pipeline of novel microbiome therapies across oncology

← Back to resources

Sponsor story

MaaT Pharma: Advancing a pipeline of novel microbiome therapies across oncology

MaaT Pharma: Advancing a pipeline of novel microbiome therapies across oncology
GastrointestinalHematologicB cell assaysT cell assaysTumor killing assaysImmune/tumor cell co-cultureMouseRNAseq
Bastien Laperrousaz Maat Pharma
Bastien Laperrousaz, PhD
Director of Preclinical Development·MaaT Pharma

With over 15 years of experience in preclinical drug development, Bastien has led programs across immuno-oncology, microbiotherapies, and cancer resistance. His expertise includes 3D cancer models, translational research, and the identification of diagnostic, prognostic, and therapeutic targets.

Maat Pharma
Who we are

At MaaT Pharma, we develop innovative microbiome therapies designed to modulate the immune system and improve outcomes for patients with severe oncology diseases.

Our pipeline spans both hematology and immuno-oncology. MaaT013 (Xervyteg®) is being developed for gastrointestinal acute Graft-versus-Host Disease (GI-aGvHD) following hematopoietic stem cell transplantation and is currently under regulatory review in Europe. We are also advancing next-generation co-cultured microbiome therapies for solid tumors, which are designed to restore immune balance and help strengthen anti-tumor responses in combination with immune checkpoint inhibitors.

Our challenge

Across our pipeline, we wanted to deepen the mechanistic understanding of our microbiome ecosystem therapies. For MaaT013 (Xervyteg®), the objective was to better characterize its immunoregulatory activity in GI-aGvHD. For our MaaT03X candidates, the goal was to evaluate their ability to activate immune cells and drive stronger effector-cell anti-tumor responses, with or without immune checkpoint inhibitors.

What Explicyte did

For our MaaT03X program, Explicyte designed a stepwise experimental strategy that first assessed activity in PBMCs, B cells, and T cells, and then evaluated each candidate’s ability to enhance the anti-tumor activity of effector cells. Their team also conducted ex vivo analyses on samples generated from animal studies. In parallel, for our MaaT013 (Xervyteg®) program, Explicyte performed in-depth ex vivo analyses to help characterize its mechanism of action in a biologically relevant setting.

The outcome

These studies helped move our preclinical programs forward, supported by structured, decision-ready reports. Explicyte demonstrated strong expertise across both immunostimulatory and immunoregulatory pathways, while their regular, transparent communication helped facilitate project follow-up and decision-making.

Could your program use this approach?

Start a conversation
← Back to resources

Explicyte Oncology CRO logo

The precision oncology CRO

229 cours de l’Argonne
33000 Bordeaux, France

Subscribe to our newsletter

By subscribing, you agree to receive Explicyte’s email updates, tailored to your interests based on the emails you open and the links you click. You can unsubscribe at any time. Privacy policy

Explicyte

  • About us
  • Commitments
  • News & Press
  • Careers
  • Contact

Discovery

  • FFPE tissues
  • Target identification
  • Target expression
  • Spatial biology for AI
  • 10x CSP services

Preclinical

  • Tumor killing
  • Immuno-modulation
  • Cytokine release
  • Patient-derived 3D models
  • ADC, Multispecifics

Trials

  • Transcriptomics
  • Peripheral markers
  • ISO-certified pathology
  • TLS detection

Multiomics

  • Atera
  • Xenium
  • Visium HD
  • scRNAseq
  • Digital pathology
  • Bioinformatics

Resources

  • Publications
  • Posters
  • Events & webinars
  • Case studies
  • IO targets database

© 2026 Explicyte. All rights reserved.

© 2026 Explicyte. All rights reserved.

    • Privacy policy
    • Terms of Use
    • Terms of service

 

Linkedin Youtube
Explicyte

Oncology CRO

Also at Explicyte Multi-Omics services Spatial Biology, scRNA-seq, Proteomics, Flow Cytometry, Bioinformatics 10x Genomics Certified Service Provider

Discovery

Overview
  • Custom biospecimen sourcing
  • Target identification & ranking
  • Target expression profiling
  • AI-Ready spatial biology datasets
10x Genomics Certified Service Provider

Preclinical

Overview
  • Patient-derived 3D tumor models
  • Xenium STAMP single-cell profiling

Tumor killing assays

Overview
  • ADCC
  • T-cell killing
  • Antigen-specific killing

Immune modulation assays

Overview
  • Immune cell activation
  • Cell Migration
  • Mixed lymphocyte reaction
  • Macrophage polarization
  • Germinal center reaction
  • Cytokine release

Modality-specific assays

Overview
  • Multispecifics & engagers
  • Antibody-drug conjugates (ADC)

Trials

Overview
  • Peripheral biomarker analysis
  • Transcriptomic biomarkers
  • ISO-certified pathology services
  • Multiplex IF panel for TLS scoring
10x Genomics Certified Service Provider
Certified IHC/IF tissue biomarker services ISO 9001 and ISO 13485 certified

Resources

Overview
  • Publications
  • Case studies
  • Posters & scientific abstracts
  • IO targets database
  • Events & webinars
  • News & press

About

Overview
  • Company
  • Commitments
  • Careers
Contact us